{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:39:15Z","timestamp":1794454755891,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This phase 1, open-label, nonrandomized, dose-escalation study evaluated MP0317 (FAP x CD40 DARPin) in adults with advanced solid tumors. Forty-six patients across nine cohorts received MP0317 at doses ranging from 0.03 to 10\u2009mg\u2009kg\n                    <jats:sup>\u22121<\/jats:sup>\n                    intravenously weekly or every 3 weeks. The primary outcome measure was safety; secondary and exploratory outcome measures included antitumor activity, pharmacokinetics and pharmacodynamics. Most treatment-related adverse events were of grades 1 and 2 (95%); a maximum tolerated dose was not reached. One patient achieved an unconfirmed partial response and 14 patients had stable disease. MP0317 serum pharmacokinetics confirmed extended half-life properties; terminal half-life estimates increased with dose and ranged from 21.8 to 120\u2009h. Paired tumor biopsies confirmed colocalization of MP0317 with fibroblast activation protein and CD40. Activation of the CD40 pathway in the tumor microenvironment was shown by increased infiltration of antigen-presenting, plasma and follicular helper T cells, dendritic cell maturation, interferon-\u03b3 signaling and circulating immune markers. Collectively, these data confirm a favorable safety profile for MP0317 and support further clinical evaluation in combination with complementary immunotherapies. ClinicalTrials.gov registration:\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\/study\/NCT05098405\" ext-link-type=\"uri\">NCT05098405<\/jats:ext-link>\n                    .\n                  <\/jats:p>","DOI":"10.1038\/s43018-026-01150-1","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T09:01:53Z","timestamp":1777626113000},"page":"810-822","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2989-2279","authenticated-orcid":false,"given":"Neeltje","family":"Steeghs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Gomez-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iphig\u00e9nie","family":"Korakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eelke","family":"Gort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-4315","authenticated-orcid":false,"given":"Hilde","family":"De Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Stojcheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3000-2205","authenticated-orcid":false,"given":"Vaia","family":"Stavropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Baverel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Florescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Hoenig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-486X","authenticated-orcid":false,"given":"Michael Peter","family":"Sanderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Kirkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Legenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3857-1688","authenticated-orcid":false,"given":"Philippe Alexandre","family":"Cassier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"1150_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2009.00782.x","volume":"229","author":"R Elgueta","year":"2009","unstructured":"Elgueta, R. et al. Molecular mechanism and function of CD40\/CD40L engagement in the immune system. Immunol. Rev. 229, 152\u2013172 (2009).","journal-title":"Immunol. Rev."},{"key":"1150_CR2","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jlb.67.1.2","volume":"67","author":"C van Kooten","year":"2000","unstructured":"van Kooten, C. & Banchereau, J. CD40-CD40 ligand. J. Leukoc. Biol. 67, 2\u201317 (2000).","journal-title":"J. Leukoc. Biol."},{"key":"1150_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","volume":"17","author":"GL Beatty","year":"2017","unstructured":"Beatty, G. L., Li, Y. & Long, K. B. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev. Anticancer Ther. 17, 175\u2013186 (2017).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"1150_CR4","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty, G. L. et al. CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612\u20131616 (2011).","journal-title":"Science"},{"key":"1150_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.5009\/gnl210311","volume":"16","author":"CY Lim","year":"2021","unstructured":"Lim, C. Y., Chang, J. H., Lee, W. S., Kim, J. & Park, I. Y. CD40 agonists alter the pancreatic cancer microenvironment by shifting the macrophage phenotype toward M1 and suppress human pancreatic cancer in organotypic slice cultures. Gut Liver 16, 645\u2013659 (2021).","journal-title":"Gut Liver"},{"key":"1150_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2019","unstructured":"Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47\u201358 (2019).","journal-title":"Annu. Rev. Med."},{"key":"1150_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1158\/1078-0432.CCR-12-2064","volume":"19","author":"RH Vonderheide","year":"2013","unstructured":"Vonderheide, R. H. & Glennie, M. J. Agonistic CD40 antibodies and cancer therapy. Clin. Cancer Res. 19, 1035\u20131043 (2013).","journal-title":"Clin. Cancer Res."},{"key":"1150_CR8","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.cytogfr.2023.11.002","volume":"75","author":"Y Zhou","year":"2024","unstructured":"Zhou, Y., Richmond, A. & Yan, C. Harnessing the potential of CD40 agonism in cancer therapy. Cytokine Growth Factor Rev. 75, 40\u201356 (2024).","journal-title":"Cytokine Growth Factor Rev."},{"key":"1150_CR9","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.4049\/jimmunol.1202017","volume":"189","author":"LP Ganesan","year":"2012","unstructured":"Ganesan, L. P. et al. Fc\u03b3RIIb on liver sinusoidal endothelium clears small immune complexes. J. Immunol. 189, 4981\u20134988 (2012).","journal-title":"J. Immunol."},{"key":"1150_CR10","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.146314","volume":"6","author":"ML Stone","year":"2021","unstructured":"Stone, M. L. et al. TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy. JCI Insight 6, e146314 (2021).","journal-title":"JCI Insight"},{"key":"1150_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005718","volume":"11","author":"M Pfefferl\u00e9","year":"2023","unstructured":"Pfefferl\u00e9, M. et al. Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity. J. Immunother. Cancer 11, e005718 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1150_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000624","volume":"8","author":"C Bonnans","year":"2020","unstructured":"Bonnans, C. et al. CD40 agonist-induced IL-12p40 potentiates hepatotoxicity. J. Immunother. Cancer 8, e000624 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"1150_CR13","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1182\/blood-2010-01-265280","volume":"116","author":"HM Horton","year":"2010","unstructured":"Horton, H. M. et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 116, 3004\u20133012 (2010).","journal-title":"Blood"},{"key":"1150_CR14","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.ccell.2018.03.008","volume":"33","author":"RH Vonderheide","year":"2018","unstructured":"Vonderheide, R. H. The immune revolution: a case for priming, not checkpoint. Cancer Cell 33, 563\u2013569 (2018).","journal-title":"Cancer Cell"},{"key":"1150_CR15","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/14712598.2024.2357714","volume":"24","author":"H Andersson","year":"2024","unstructured":"Andersson, H. et al. Next-generation CD40 agonists for cancer immunotherapy. Expert Opin. Biol. Ther. 24, 351\u2013363 (2024).","journal-title":"Expert Opin. Biol. Ther."},{"key":"1150_CR16","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-10-2888","volume":"17","author":"MF Fransen","year":"2011","unstructured":"Fransen, M. F., Sluijter, M., Morreau, H., Arens, R. & Melief, C. J. M. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin. Cancer Res. 17, 2270\u20132280 (2011).","journal-title":"Clin. Cancer Res."},{"key":"1150_CR17","doi-asserted-by":"publisher","first-page":"11048","DOI":"10.1073\/pnas.1810566115","volume":"115","author":"DA Knorr","year":"2018","unstructured":"Knorr, D. A., Dahan, R. & Ravetch, J. V. Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity. Proc. Natl Acad. Sci. USA 115, 11048\u201311053 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1150_CR18","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1158\/2326-6066.CIR-21-0553","volume":"10","author":"N Rigamonti","year":"2022","unstructured":"Rigamonti, N. et al. A multispecific anti-CD40 DARPin construct induces tumor-selective CD40 activation and tumor regression. Cancer Immunol. Res. 10, 626\u2013640 (2022).","journal-title":"Cancer Immunol. Res."},{"key":"1150_CR19","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.2741\/4682","volume":"23","author":"P Busek","year":"2018","unstructured":"Busek, P., Mateu, R., Zubal, M., Kotackova, L. & Sedo, A. Targeting fibroblast activation protein in cancer\u2014Prospects and caveats. Front. Biosci. 23, 1933\u20131968 (2018).","journal-title":"Front. Biosci."},{"key":"1150_CR20","doi-asserted-by":"publisher","first-page":"12139","DOI":"10.1073\/pnas.1412910111","volume":"111","author":"AE Denton","year":"2014","unstructured":"Denton, A. E., Roberts, E. W., Linterman, M. A. & Fearon, D. T. Fibroblastic reticular cells of the lymph node are required for retention of resting but not activated CD8+ T cells. Proc. Natl Acad. Sci. USA 111, 12139\u201312144 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1150_CR21","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.fob.2013.12.001","volume":"4","author":"FM Keane","year":"2014","unstructured":"Keane, F. M. et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio 4, 43\u201354 (2014).","journal-title":"FEBS Open Bio"},{"key":"1150_CR22","first-page":"10","volume":"5","author":"H Dolznig","year":"2005","unstructured":"Dolznig, H. et al. Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin. Cancer Immun. 5, 10 (2005).","journal-title":"Cancer Immun."},{"key":"1150_CR23","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil, C. et al. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J. Nucl. Med. 60, 801\u2013805 (2019).","journal-title":"J. Nucl. Med."},{"key":"1150_CR24","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.92232","volume":"2","author":"A Lo","year":"2017","unstructured":"Lo, A. et al. Fibroblast activation protein augments progression and metastasis of pancreatic ductal adenocarcinoma. JCI Insight 2, e92232 (2017).","journal-title":"JCI Insight"},{"key":"1150_CR25","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1084\/jem.20130110","volume":"210","author":"E Tran","year":"2013","unstructured":"Tran, E. et al. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J. Exp. Med. 210, 1125\u20131135 (2013).","journal-title":"J. Exp. Med."},{"key":"1150_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/cells12151926","volume":"12","author":"A Klersy","year":"2023","unstructured":"Klersy, A. et al. Ectodomain shedding by ADAM17 increases the release of soluble CD40 from human endothelial cells under pro-inflammatory conditions. Cells 12, 1926 (2023).","journal-title":"Cells"},{"key":"1150_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/1750743X.2024.2359359","volume":"16","author":"B Tran","year":"2024","unstructured":"Tran, B. et al. A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors. Immunotherapy 16, 759\u2013774 (2024).","journal-title":"Immunotherapy"},{"key":"1150_CR28","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","volume":"21","author":"P Johnson","year":"2015","unstructured":"Johnson, P. et al. Clinical and biological effects of an agonist anti-CD40 antibody: a cancer research UK phase I study. Clin. Cancer Res. 21, 1321\u20131328 (2015).","journal-title":"Clin. Cancer Res."},{"key":"1150_CR29","doi-asserted-by":"publisher","first-page":"228","DOI":"10.3109\/10428190903440946","volume":"51","author":"RR Furman","year":"2010","unstructured":"Furman, R. R., Forero-Torres, A., Shustov, A. & Drachman, J. G. A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 51, 228\u2013235 (2010).","journal-title":"Leuk. Lymphoma"},{"key":"1150_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006133","volume":"11","author":"JSS Narayanan","year":"2023","unstructured":"Narayanan, J. S. S. et al. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model. J. Immunother. Cancer 11, e006133 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"1150_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202206873","volume":"10","author":"H-C Liu","year":"2023","unstructured":"Liu, H.-C. et al. Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer. Adv. Sci. 10, 2206873 (2023).","journal-title":"Adv. Sci."},{"key":"1150_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005018","volume":"10","author":"K H\u00e4gerbrand","year":"2022","unstructured":"H\u00e4gerbrand, K. et al. Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies. J. Immunother. Cancer 10, e005018 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1150_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002015","volume":"9","author":"JJ Luke","year":"2021","unstructured":"Luke, J. J. et al. Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors. J. Immunother. Cancer 9, e002015 (2021).","journal-title":"J. Immunother. Cancer"},{"key":"1150_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003264","volume":"10","author":"E Sum","year":"2022","unstructured":"Sum, E. et al. The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. J. Immunother. Cancer 10, e003264 (2022).","journal-title":"J. Immunother. Cancer"},{"key":"1150_CR35","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1158\/1078-0432.CCR-20-4001","volume":"27","author":"E Sum","year":"2021","unstructured":"Sum, E. et al. Fibroblast activation protein \u03b1-targeted CD40 agonism abrogates systemic toxicity and enables administration of high doses to induce effective antitumor immunity. Clin. Cancer Res. 27, 4036\u20134053 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1150_CR36","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1007\/s13346-023-01308-9","volume":"13","author":"S Shahvali","year":"2023","unstructured":"Shahvali, S., Rahiman, N., Jaafari, M. R. & Arabi, L. Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy. Drug Deliv. Transl. Res. 13, 2041\u20132056 (2023).","journal-title":"Drug Deliv. Transl. Res."},{"key":"1150_CR37","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10637-022-01319-2","volume":"41","author":"V Moreno","year":"2023","unstructured":"Moreno, V. et al. A phase 1 study of intravenous mitazalimab, a CD40 agonistic monoclonal antibody, in patients with advanced solid tumors. Invest. New Drug 41, 93\u2013104 (2023).","journal-title":"Invest. New Drug"},{"key":"1150_CR38","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1158\/1078-0432.CCR-21-0903","volume":"27","author":"SA Weiss","year":"2021","unstructured":"Weiss, S. A. et al. A phase I study of APX005M and cabiralizumab with or without nivolumab in patients with melanoma, kidney cancer, or non-small cell lung cancer resistant to anti-PD-1\/PD-L1. Clin. Cancer Res. 27, 4757\u20134767 (2021).","journal-title":"Clin. Cancer Res."},{"key":"1150_CR39","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1038\/s44161-025-00633-1","volume":"4","author":"J Jimenez","year":"2025","unstructured":"Jimenez, J. et al. The immune checkpoint regulator CD40 potentiates myocardial inflammation. Nat. Cardiovasc. Res. 4, 458\u2013472 (2025).","journal-title":"Nat. Cardiovasc. Res."},{"key":"1150_CR40","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41586-024-08008-5","volume":"635","author":"JM Amrute","year":"2024","unstructured":"Amrute, J. M. et al. Targeting immune\u2013fibroblast cell communication in heart failure. Nature 635, 423\u2013433 (2024).","journal-title":"Nature"},{"key":"1150_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132044","volume":"406","author":"J Tillmanns","year":"2024","unstructured":"Tillmanns, J. et al. Circulating soluble fibroblast activation protein (FAP) levels are independent of cardiac and extra-cardiac FAP expression determined by targeted molecular imaging in patients with myocardial FAP activation. Int. J. Cardiol. 406, 132044 (2024).","journal-title":"Int. J. Cardiol."},{"key":"1150_CR42","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/s41571-022-00619-z","volume":"19","author":"WH Fridman","year":"2022","unstructured":"Fridman, W. H. et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat. Rev. Clin. Oncol. 19, 441\u2013457 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1150_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1515\/bmc-2018-0007","volume":"9","author":"G Kak","year":"2018","unstructured":"Kak, G., Raza, M. & Tiwari, B. K. Interferon-gamma (IFN-\u03b3): exploring its implications in infectious diseases. Biomol. Concepts 9, 64\u201379 (2018).","journal-title":"Biomol. Concepts"},{"key":"1150_CR44","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1016\/j.immuni.2023.08.015","volume":"56","author":"NM Arroyo-D\u00edaz","year":"2023","unstructured":"Arroyo-D\u00edaz, N. M. et al. Interferon-\u03b3 production by Tfh cells is required for CXCR3+ pre-memory B cell differentiation and subsequent lung-resident memory B cell responses. Immunity 56, 2358\u20132372 (2023).","journal-title":"Immunity"},{"key":"1150_CR45","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Invest."},{"key":"1150_CR46","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/s43018-025-00986-3","volume":"6","author":"K Aliazis","year":"2025","unstructured":"Aliazis, K. et al. The tumor microenvironment\u2019s role in the response to immune checkpoint blockade. Nat. Cancer 6, 924\u2013937 (2025).","journal-title":"Nat. Cancer"},{"key":"1150_CR47","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549\u2013555 (2020).","journal-title":"Nature"},{"key":"1150_CR48","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","volume":"55","author":"M Meylan","year":"2022","unstructured":"Meylan, M. et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 55, 527\u2013541 (2022).","journal-title":"Immunity"},{"key":"1150_CR49","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman, C., Florent, P., Julien, C. & Fridman, W. H. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat. Rev. Cancer 19, 307\u2013325 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"1150_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29040-x","volume":"13","author":"N Horeweg","year":"2022","unstructured":"Horeweg, N. et al. Tertiary lymphoid structures critical for prognosis in endometrial cancer patients. Nat. Commun. 13, 1373 (2022).","journal-title":"Nat. Commun."},{"key":"1150_CR51","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.7150\/ijms.56347","volume":"18","author":"Z Zhao","year":"2021","unstructured":"Zhao, Z. et al. Relationship between tertiary lymphoid structure and the prognosis and clinicopathologic characteristics in solid tumors. Int. J. Med. Sci. 18, 2327\u20132338 (2021).","journal-title":"Int. J. Med. Sci."},{"key":"1150_CR52","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","volume":"2","author":"L Vanhersecke","year":"2021","unstructured":"Vanhersecke, L. et al. Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nat. Cancer 2, 794\u2013802 (2021).","journal-title":"Nat. Cancer"},{"key":"1150_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.674565","volume":"12","author":"M Tr\u00fcb","year":"2021","unstructured":"Tr\u00fcb, M. & Zippelius, A. Tertiary lymphoid structures as a predictive biomarker of response to cancer immunotherapies. Front. Immunol. 12, 674565 (2021).","journal-title":"Front. Immunol."},{"key":"1150_CR54","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1038\/nbt1039","volume":"22","author":"S Suematsu","year":"2004","unstructured":"Suematsu, S. & Watanabe, T. Generation of a synthetic lymphoid tissue-like organoid in mice. Nat. Biotechnol. 22, 1539\u20131545 (2004).","journal-title":"Nat. Biotechnol."},{"key":"1150_CR55","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.3389\/fimmu.2018.01609","volume":"9","author":"G Zhu","year":"2018","unstructured":"Zhu, G. et al. Induction of tertiary lymphoid structures with antitumor function by a lymph node-derived stromal cell line. Front. Immunol. 9, 1609 (2018).","journal-title":"Front. Immunol."},{"key":"1150_CR56","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.1073\/pnas.1918971117","volume":"117","author":"AH Morrison","year":"2020","unstructured":"Morrison, A. H., Diamond, M. S., Hay, C. A., Byrne, K. T. & Vonderheide, R. H. Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity. Proc. Natl Acad. Sci. USA 117, 8022\u20138031 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1150_CR57","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar, G. et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides\u2014Harmonized terminology and tactical recommendations. AAPS J. 16, 658\u2013673 (2014).","journal-title":"AAPS J."},{"key":"1150_CR58","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"1150_CR59","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1093\/bioinformatics\/bty896","volume":"35","author":"RV Alvarez","year":"2019","unstructured":"Alvarez, R. V., Pongor, L. S., Mari\u00f1o-Ram\u00edrez, L. & Landsman, D. TPMCalculator: one-step software to quantify mRNA abundance of genomic features. Bioinformatics 35, 1960\u20131962 (2019).","journal-title":"Bioinformatics"},{"key":"1150_CR60","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1158\/2159-8290.CD-20-0839","volume":"11","author":"N Kotlov","year":"2021","unstructured":"Kotlov, N. et al. Clinical and biological subtypes of B-cell lymphoma revealed by microenvironmental signatures. Cancer Discov. 11, 1468\u20131489 (2021).","journal-title":"Cancer Discov."},{"key":"1150_CR61","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41591-022-01829-9","volume":"28","author":"LJ Padr\u00f3n","year":"2022","unstructured":"Padr\u00f3n, L. J. et al. Sotigalimab and\/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial. Nat. Med. 28, 1167\u20131177 (2022).","journal-title":"Nat. Med."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01150-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01150-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01150-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:01:54Z","timestamp":1780063314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01150-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":61,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["1150"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01150-1","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"20 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N. Steeghs provided consultation or attended advisory boards for Boehringer Ingelheim, Bristol Myers Squibb, Ellipses Pharma, GlaxoSmithKline and Incyte. She received research grants from Abbvie, Actuate Therapeutics, Amgen, Anaveon, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb, CellCentric, Cogent Biosciences, Crescendo Biologics, Deciphera, Exelixis, Genentech, GlaxoSmithKline, IDRx, Immunocore, Incyte, Janssen, Kling Biotherapeutics, Lixte, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Novartis, Pfizer, Revolution Medicines, Roche, Sanofi, Seattle Genetics and Zentalis. All were outside the submitted work; all payment was made to the Netherlands Cancer Institute. C.G.-R. has received honoraria and consulting fees from Regeneron Therapeutics, Pierre Fabre, Bristol Myers Squibb, Roche-Genentech; travel support from Merck Sharp & Dohme, Roche-Genentech and Pierre Fabre; participation on data safety monitoring or advisory board for Pharmamar and Macomics; and funding to institution for the conduct of clinical research from Abbvie, Amunix, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Dragonfly, Ideaya, Incyte, Kazia, Eli Lilly\/Loxo, Molecular Partners, Ose Immunotherapeutics, Roche-Genentech, Sotio and Tango, and had leadership roles at the European Society For Medical Oncology and FITC. I.K. has received travel support from Roche; honoraria from Merck Sharp & Dohme for oral presentations; and funding to institution for the conduct of clinical research from Abbvie, Amgen, ANAVEON, C4 Therapeutics, Daiichi Sankyo, Dragonfly, Molecular Partners, Imcheck Therapeutics and Sotio. H.D.W., N. Stojcheva, V.S., J.K., P.B., E.F., A.M.F., L.H., M.P.S., V.K. and P.L. are or were employees of Molecular Partners when the study was conducted and the manuscript prepared; they also have stock ownership. P.A.C. has received honoraria from Boehringer Ingelheim, Brenus, Bristol Myers Squibb, Ose Immunotherapeutics and Scenic; travel support from Novartis and Pierre Fabre; nonfinancial support from Debiopharm, GlaxoSmithKline and Novartis; and funding to institution for the conduct of clinical research from Abbvie, ADCT, Adlai Nortye, Amgen, Boehringer Ingelheim, Blueprint, C4 Therapeutics, Debio Pharm, Daiichi Sankyo, Dragonfly, Exelixis, Incyte, Iteos, Janssen, Eli Lilly\/Loxo, Molecular Partners, Novartis, Ose Immunotherapeutics, Relay, Roche\/Genentech, Sotio, Taiho, Tango, Toray and Transgene. E.G. declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}